05 October 2022
EMA/CAT/772339/2022
Human Medicines Division

Committee for Advanced Therapies (CAT)
Draft agenda for the meeting on 05-07 October 2022

Chair: Martina Schuessler-Lenz; Vice-Chair: Ilona Reischl

05 October 2022, 14:00 – 18:30, room 01-D
06 October 2022, 09:00 – 18:30, room 01-D
07 October 2022, 09:00 – 13:00, room 01-D

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

## 1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts .......... 5
1.2. Adoption of agenda ........................................................................................................ 5
1.3. Adoption of the minutes .............................................................................................. 5

## 2. Evaluation of ATMPs

2.1. Opinions ................................................................................................................... 5
2.1.1. Tableleucel - PRIME - Orphan - EMEA/H/C/004577 ...................................................... 5
2.2. Oral explanations ........................................................................................................ 5
2.3. Day 180 list of outstanding issues ........................................................................... 5
2.3.1. Etranacogene dezaparvovec - PRIME - Orphan - EMEA/H/C/004827 ......................... 5
2.4. Day 120 list of questions .......................................................................................... 6
2.5. Day 80 assessment reports ....................................................................................... 6
2.6. Update on ongoing initial applications ..................................................................... 6
2.7. New applications ...................................................................................................... 6
2.8. Withdrawal of initial marketing authorisation application .................................... 6
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 ................................................................................................................. 6
2.10. GMP and GCP inspections requests ......................................................................... 6
2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ................................................................. 6
2.11.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003 ................................................................................................................................. 6
2.11.2. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0057 ......................................... 6
2.11.3. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0053 ............................. 7
2.11.4. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0059 ............................. 7
2.12. Extension applications ............................................................................................. 7
2.13. Other Post-Authorisation Activities ....................................................................... 8
2.13.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/002 ................................................................................................................................. 8
2.13.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/003 ................................................................................................................................. 8
2.13.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/011 ................................................................................................................................. 8
2.13.4. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/012 ................................................................................................................................. 8
2.13.5. Luxturna - voretigene neparvovec - Orphan - EMEA/H/C/004451/REC/009 ................. 8
2.13.6. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/SOB/002 ............ 9
3. Certification of ATMPs

3.1. Opinion

3.2. Day 60 Evaluation Reports

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Allogeneic adipose-derived mesenchymal stem cells (ADMSCs)

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic adipose derived mesenchymal stem cells

4.2.2. Autologous adipose derived mesenchymal stem cells

4.2.3. Autologous anti-BCMA CAR-T cells

4.2.4. Allogeneic latency-2 Epstein-Barr virus-targeted cytotoxic T lymphocytes

4.2.5. E1-deleted (replication defective) recombinant human adenovirus serotype 5 expressing TIMP3 (tissue inhibitor of metalloproteinases-3) under the control of the cytomegalovirus immediate early promoter

4.2.6. Autologous CD34+ cells transfected with a lentiviral vector containing codon-optimised RPS19 gene

4.3. Day 60 revised scientific recommendation (following list of questions)

4.4. Finalisation of procedure

4.4.1. Autologous cultured limbal epithelial and limbal epithelial stem cells growing on fibrin scaffold

4.4.2. Human allogeneic cardiac progenitor cell subpopulation selected for the absence of the surface marker CD90

4.4.3. Allogeneic CD33-directed genetically modified T-cell immunotherapy

4.4.4. Allogeneic CRISPR/Cas9-edited hematopoietic stem and progenitor cells (HSPCs) lacking CD33 protein expression

4.5. Follow-up and guidance

4.5.1. Ex-vivo expanded allogeneic human corneal epithelial cells containing P63 positively expressing cells

5. Scientific Advice

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs
6.3. Priority Medicines (PRIME) – Eligibility requests ................................................. 13
6.3.1. Month 0 - Start of the procedure ......................................................................... 13
6.3.2. Month 1 – Discussion of eligibility .................................................................... 13
6.3.3. Month 2 – Recommendation of eligibility ......................................................... 13
6.3.4. Ongoing support ............................................................................................... 13

7. Organisational, regulatory and methodological matters ........................................ 13
7.1. Mandate and organisation of the CAT ................................................................. 13
7.1.1. CAT membership ............................................................................................. 13
7.1.2. Vote by proxy .................................................................................................. 13
7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Czechia presidency, 17 – 18 November 2022 in Paris ................................................................. 13
7.1.4. Update on procedure for Chair election .......................................................... 14
7.2. Coordination with EMA Scientific Committees ................................................. 14
7.2.1. Guideline on Safety and Efficacy Follow-up and RMP ...................................... 14
7.2.2. Scientific coordination board ........................................................................... 14
7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ...... 14
7.3.1. Reflection paper on criteria to be considered for the evaluation of new active substance (NAS) status of biological substances ................................................ 14
7.4. Cooperation with the EU regulatory network ..................................................... 14
7.4.1. Regulatory & scientific conference on RNA-based medicines .......................... 14
7.4.2. Revision of the EU legislation on blood, tissues and cells (BTC) ...................... 14
7.5. Cooperation with international regulators ......................................................... 15
7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan) 15
7.5.2. WHO approach towards the development of a global regulatory framework for cell and gene therapy products .......................................................... 15
7.6. CAT work plan ................................................................................................ 15
7.6.1. CAT Workplan for 2023 ................................................................................ 15
7.7. Planning and reporting ...................................................................................... 15
7.8. Others ............................................................................................................. 15
7.8.1. Adeno-associated viral (AAV) vector toxicities: regulatory considerations .... 15
7.8.2. DARWIN EU Coordination Centre ................................................................. 15
7.8.3. Update on Clinical Trials Raw Data pilot ....................................................... 15
7.8.4. EMA Pilot – enhanced support to academic and non-profit ATMP developers 16

8. Any other business ............................................................................................ 16
9. Explanatory notes ............................................................................................... 17
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 05-07 October 2022. See 05-07 October 2022 CAT minutes (to be published post 03-04 November 2022 CAT meeting).

1.2. **Adoption of agenda**

CAT agenda for 05-07 October 2022 meeting

1.3. **Adoption of the minutes**

CAT minutes for 07-09 September 2022 meeting

2. **Evaluation of ATMPs**

2.1. **Opinions**

2.1.1. **Tabelecleucel - PRIME - Orphan - EMEA/H/C/004577**

Atara Biotherapeutics Ireland Limited; treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV⁺ PTLD)

Scope: Opinion

**Action:** for adoption

List of Questions adopted on 18.03.2022; List of outstanding issue adopted on 09.09.2022.

2.2. **Oral explanations**

No items

2.3. **Day 180 list of outstanding issues**

2.3.1. **Etranacogene dezaparvovec - PRIME - Orphan - EMEA/H/C/004827**

CSL Behring GmbH; treatment of adults with Haemophilia B

Scope: Day 180 list of outstanding issues

**Action:** for adoption
List of Questions adopted on 15.07.2022.

2.4. **Day 120 list of questions**
No items

2.5. **Day 80 assessment reports**
No items

2.6. **Update on ongoing initial applications**
No items

2.7. **New applications**

2.8. **Withdrawal of initial marketing authorisation application**
No items

2.9. **Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004**
No items

2.10. **GMP and GCP inspections requests**
No items

2.11. **Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

2.11.1. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality. Request for Supplementary Information

**Action:** for adoption
Request for Supplementary Information adopted on 15.07.2022.

2.11.2. **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0057**

Amgen Europe B.V.
Rapporteur: Maija Tarkkanen
Scope: Safety. Opinion

Update to sections 4.4 and 4.8 of the SmPC to revise the safety instructions regarding the risk of disseminated herpetic infection adverse drug reactions following an MAH review of aggregate safety data of herpetic and disseminated herpetic infections that were reported in patients who were not immunocompromised and those who were immunocompromised. The Package Leaflet is updated accordingly.

**Action:** for adoption

2.11.3. **Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0053**

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Clinical. Opinion

Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation in the Annex II of the Product Information. This is a randomized open-label parallel-group multicentre Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immune-chemotherapy. The Annex II is updated accordingly.

**Action:** for adoption

Request for Supplementary Information adopted on 13.05.2022.

2.11.4. **Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0059**

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Safety and efficacy. Opinion

Update of section 5.1 of the SmPC based on a subgroup analysis from CCTL019B2401 (B2401) disease registry listed as a PAES (ANX006) in the Annex II; this is a non-interventional study to evaluate the efficacy and safety of Kymriah in ALL patients below the age of 3 years. In addition, the MAH took the opportunity to update Annex II.D of the SmPC to reflect the fulfilment of the PAES.

**Action:** for adoption

Request for Supplementary Information adopted on 15.07.2022.

2.12. **Extension applications**

No items
2.13. **Other Post-Authorisation Activities**

2.13.1. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/002**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani
Scope: Quality
**Action:** for adoption

2.13.2. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/003**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality
**Action:** for adoption

2.13.3. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/011**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality
**Action:** for adoption

2.13.4. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/012**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality
**Action:** for adoption

2.13.5. **Luxturna - voretigene neparvovec - Orphan - EMEA/H/C/004451/REC/009**

Novartis Europharm Limited
Rapporteur: Sol Ruiz
Scope: Quality
**Action:** for adoption
2.13.6. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/SOB/002

PTC Therapeutics International Limited

Rapporteur: Maura O'Donovan

Scope: Study PTC-AADC-MA-406: a real-world, multicentre, observational and longitudinal study of patients with aromatic L amino acid decarboxylase (AADC) deficiency and with a severe phenotype treated with Upstaza globally, based on data from a registry, according to an agreed protocol. From initial MAA.

Action: for adoption

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:
- Start of the procedure: 07.10.2022
- EMA Coordinator's draft report: 21.10.2022
- CAT Coordinator's comments: 26.10.2022
- Revised scientific recommendation: 28.10.2022
- CAT's discussion of scientific recommendation: 04.11.2022

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Allogeneic adipose-derived mesenchymal stem cells (ADMSCs)

Intended for the treatment of osteoarthritis of the knee and hip

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption
4.2. **Day 30 ATMP scientific recommendation**

4.2.1. **Allogeneic adipose derived mesenchymal stem cells**

Intended for the treatment of Crohn-related perianal fistula  
Scope: ATMP scientific recommendation  
**Action:** for adoption

4.2.2. **Autologous adipose derived mesenchymal stem cells**

Intended for the treatment of Crohn-related perianal fistula  
Scope: ATMP scientific recommendation  
**Action:** for adoption

4.2.3. **Autologous anti-BCMA CAR-T cells**

Intended for the treatment of multiple myeloma  
Scope: ATMP scientific recommendation  
**Action:** for adoption

4.2.4. **Allogeneic latency-2 Epstein-Barr virus-targeted cytotoxic T lymphocytes**

Intended for the treatment of multiple sclerosis  
Scope: ATMP scientific recommendation  
**Action:** for adoption

4.2.5. **E1-deleted (replication defective) recombinant human adenovirus serotype 5 expressing TIMP3 (tissue inhibitor of metalloproteinases-3) under the control of the cytomegalovirus immediate early promoter**

Intended for the treatment of coronary artery disease requiring artery bypass grafting (CABG)  
Scope: ATMP scientific recommendation  
**Action:** for adoption

4.2.6. **Autologous CD34+ cells transfected with a lentiviral vector containing codon-optimised RPS19 gene**

Intended for the treatment of transfusion-dependent, steroid-resistant paediatric patients with Diamond-Blackfan anaemia, who have a mutation in the RPS19 gene  
Scope: ATMP scientific recommendation  
**Action:** for adoption

4.3. **Day 60 revised scientific recommendation (following list of**
4.4. **Finalisation of procedure**

4.4.1. **Autologous cultured limbal epithelial and limbal epithelial stem cells growing on fibrin scaffold**

Intended for the treatment of moderate to severe limbal stem cell deficiency (LSCD) caused by burns, including chemical burns to the eyes

Scope: The European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.2. **Human allogeneic cardiac progenitor cell subpopulation selected for the absence of the surface marker CD90**

Intended to improve cardiac perfusion and function in patients with refractory angina

Scope: The European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.3. **Allogeneic CD33-directed genetically modified T-cell immunotherapy**

Intended for the treatment of patients with CD33-positive acute myeloid leukaemia (AML) who are at a high risk of relapse

Scope: The European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.4. **Allogeneic CRISPR/Cas9-edited hematopoietic stem and progenitor cells (HSPCs) lacking CD33 protein expression**

Intended for the treatment of patients with CD33-positive acute myeloid leukaemia (AML) who are at a high risk of relapse

Scope: The European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.5. **Follow-up and guidance**

4.5.1. **Ex-vivo expanded allogeneic human corneal epithelial cells containing P63 positively expressing cells**

Intended for the treatment of persistent corneal epithelial defects

Scope: Updated ATMP scientific recommendation
**Action:** for adoption

Note: The report has been updated following a request for clarification received from the applicant.

### 5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 5.1. New requests - appointment of CAT Rapporteurs

##### 5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

| Timetable: |  
| --- | --- |
| - Start of procedure at SAWP: | 26-29.09.2022 |
| - Appointment of CAT Peer Reviewers: | 05-07.10.2022 |
| - SAWP first reports: | 17.10.2022 |
| - CAT Peer Reviewer comments (NC,C): | 21.10.2022 |
| - CAT Peer reviewer comments (Q): | 26.10.2022 |
| - Discussion at SAWP: | 24-27.10.2022 |
| - Discussion at CAT and feedback to SAWP: | 04.11.2022 |

##### 5.1.2. Scientific advice procedures starting at the next SAWP meeting

| Timetable: |  
| --- | --- |
| - Start of procedure at SAWP: | 24-27.10.2022 |
| - Appointment of CAT Peer Reviewers: | 03-04.10.2022 |
| - SAWP first reports: | 21.11.2022 |
| - CAT Peer Reviewer comments: | 25.11.2022 |
| - Discussion at SAWP: | 30.11.2022 |
| - Discussion at CAT and feedback to SAWP: | 01.12.2022 |

#### 5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

#### 5.3. Finalisation of D70 procedures – feedback from the discussion meeting

#### 5.4. Final Advice Letters for procedures finalised the previous month

### 6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 6.1. Paediatric investigation plans

No items
6.2. **ITF briefing meetings in the field of ATMPs**

6.3. **Priority Medicines (PRIME) – Eligibility requests**

6.3.1. **Month 0 - Start of the procedure**

Timetable for assessment:
- Procedure start: 26-29.09.2022
- SAWP recommendation: 27.10.2022
- CAT recommendation: 04.11.2022
- CHMP adoption of report and final recommendation: 10.11.2022

No items

6.3.2. **Month 1 – Discussion of eligibility**

No items

6.3.3. **Month 2 – Recommendation of eligibility**

6.3.4. **Ongoing support**

No items

7. **Organisational, regulatory and methodological matters**

7.1. **Mandate and organisation of the CAT**

7.1.1. **CAT membership**

No items

7.1.2. **Vote by proxy**

No items

7.1.3. **CAT Strategic Review & Learning meeting (SRLM) under the Czechia presidency, 17 – 18 November 2022 in Paris**

CAT: Petr Soukup, Martina Schuessler-Lenz

Scope: updated agenda content

**Action:** for discussion
7.1.4. **Update on procedure for Chair election**

**Action:** for information

7.2. **Coordination with EMA Scientific Committees**

7.2.1. **Guideline on Safety and Efficacy Follow-up and RMP**

CAT: Martina Schüssler-Lenz / Ilona Reischl
Scope: Finalisation of the guideline
**Action:** for discussion

7.2.2. **Scientific coordination board**

CAT: Martina Schüssler-Lenz
Scope: oral feedback
**Action:** for information

7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

7.3.1. **Reflection paper on criteria to be considered for the evaluation of new active substance (NAS) status of biological substances**

Rapporteur: Martijn van der Plas
**Action:** For adoption

7.4. **Cooperation with the EU regulatory network**

7.4.1. **Regulatory & scientific conference on RNA-based medicines**

Scope: Draft agenda of the conference that is scheduled to take place on 2 February 2023.
**Action:** for discussion

7.4.2. **Revision of the EU legislation on blood, tissues and cells (BTC)**

CAT: Ilona Reischl
Scope: Analysis of the BTC proposal
**Action:** for information
7.5. **Cooperation with international regulators**

7.5.1. **ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)**

CAT: Martina Schuessler-Lenz
Scope: Agenda of the teleconference of 20 October 2022
**Action:** for information

7.5.2. **WHO approach towards the development of a global regulatory framework for cell and gene therapy products**

CAT: Ilona Reischl
Scope: Comments from the public consultation
**Action:** for information

7.6. **CAT work plan**

7.6.1. **CAT Workplan for 2023**

CAT: Martina Schüssler-Lenz
Scope: first reflections on CAT workplan topics for 2023
**Action:** for discussion

7.7. **Planning and reporting**

No items

7.8. **Others**

7.8.1. **Adeno-associated viral (AAV) vector toxicities: regulatory considerations**

CAT: Carla Herberots, Egbert Flory
Scope: Discussion paper on insertional mutagenesis and follow-up for AAV gene therapy
**Action:** for adoption

7.8.2. **DARWIN EU Coordination Centre**

Scope: Follow up on real world evidence (RWE) and DARWIN EU® and the recently selected data partners and year 1 RWE studies.
**Action:** for discussion

7.8.3. **Update on Clinical Trials Raw Data pilot**

Scope: Presentation of the clinical trial raw data pilot
**Action:** for information
Note: The pilot aims to assess the benefits and practicalities of access to raw data in the assessment of medicines. The pilot, expected to last up to two years, will include 10 regulatory procedures submitted to EMA from September 2022. Recent developments around EMA’s raw data pilot and next steps will be presented.

7.8.4. **EMA Pilot – enhanced support to academic and non-profit ATMP developers**

EMA: Ana Hidalgo
Scope: question and answer on the pilot
Action: for discussion
Note: EMA web announcement (29.09.2022)
EMA pilot offers enhanced support to academic and non-profit developers of advanced therapy medicinal products | European Medicines Agency (europa.eu)

8. **Any other business**

No items

Date of next CAT meeting:
03-04/11/2022
9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus
AR: Assessment Report
ATMP: Advanced Therapy Medicinal Product
BWP: Biologics Working Party
CAT: Committee for Advanced Therapies
CHMP: Committee for Medicinal Product for Human Use
COMP: Committee for Orphan Medicinal Products
CTFG: Clinical Trial Facilitation Group
DG: Drafting Group
EC: European Commission
EU NTC: European Union Network Training Centre
ERA: Environmental Risk Assessment
FDA: Food and Drug Administration
FL: Final Letter
GCG: Guideline Consistency Group
GCP: Good Clinical Practice
GLP: Good Laboratory Practice
GMO: Genetically-modified organism
GMP: Good Manufacturing Practice
GTMP: Gene Therapy Medicinal Product
HTA: Health Technology Assessment Bodies
HSPC: Hematopoietic Stem and Progenitor Cells
ITF: Innovative Task Force
JR: Joint Report
LoOI: List of outstanding issues
LoQ: List of questions
MA: Marketing Authorisation
MAA: Marketing Authorisation Application
MAH: Marketing Authorisation Holder
MNAT: Multinational assessment team
MSC: Mesenchymal stem cells
PDCO: Paediatric Committee
PMDA: Pharmaceuticals and Medical Devices Agency (Japan)
PIP: Paediatric Investigation Plan
PL: Package leaflet
PRAC: Pharmacovigilance and Risk Assessment Committee #
PRIME: Priority Medicines  
QRD: Quality review of documents  
RMP: Risk Management Plan  
RP: Reflection paper  
RSI: Request for supplementary information  
SAs: Scientific Advices  
SAG-O: Scientific Advisory Group Oncology  
SAWP: Scientific Advice Working Party  
SR: Summary Report  
SWP: Safety Working Party  
SME: Small and medium size enterprises  
SmPC: Summary of Products Characteristics  
TT: Timetable  

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.
Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)**

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

**Withdrawal of applications (section 2.7.)**

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**New applications (section 2.9.)**

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

**GMP and GCP Inspections Issues (section 2.10.)**

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Post-authorisation activities (section 2.12.)**

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

**Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

**Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

**Scientific Advice (section 5)**

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).
**Pre-Authorisation (section 6)**

**Paediatric Investigation Plan (PIP)**

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

**ITF Briefing meeting in the field of ATMPs**

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT.

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

**Priority Medicines (PRIME)**

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

**Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

**Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)